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Introduction
Homozygous missense mutation in the IL36RN gene
resulting in deficiency of interleukin-36-receptor antago-
nist (DITRA) is phenotypically presented as severe gener-
alized pustular psoriasis starting in early childhood.
Compound heterozygous cases have been described with
the same DITRA phenotype, but to our knowledge hetero-
zygous IL36RN mutation related to severe generalized







First child of non-consanguineous caucasian (Danish) par-
ents prenatally diagnosed with tetralogy of Fallot. Array
CGH revealed normal karyotype. Pregnancy and delivery
was uneventful. Mother had hemorrhagic proctitis and
psoriasis. The girl presented at 3 months of age with what
appeared as infectious dermatitis and S. aureus cultured
from skin lesions spreading to extremities and trunk.
Blood tests including acute phase reactants were normal.
She started on intravenous antibiotics and topical corticos-
teroids. During the following week the dermal changes
presented with scaly sharply demarcated psoriasiform pla-
ques. Infection was cleared and topical betamethasone
gave a partial improvement. Cardiac surgery was per-
formed at the age of 4 months. Procedures were
uncomplicated but a precipitous flare of numerous pus-
tules was then observed. Methotrexate treatment was
initiated. On suspection for DIRA or DITRA genetic test-
ing for IL1RN and IL36RN gene mutations was initiated.
The girl was found to be heterozygous for a mutation in
the IL36RN gene (exon 5, c 338C>T p Ser113Leu) whereas
the IL1RN gene (mutated in DIRA patients) was normal.
Additionally, a heterozygous mutation in the NLRP3 gene
was also found (exon 3, c.2107C>A, p.Gln703Lys)
via whole exome sequencing. Treatment with anakinra
(4 mg/kg/day) had a marked positive effect, but did not
result in total remission. MTX was increased to 15 mg/
m2/week given subcutaneously. After 8 weeks and opti-
mized doses 8 mg/kg/day of anakinra without sufficient
remission the treatment was shifted to infliximab 6.5 mg/
kg/dose on Day 0, 14, 28, hereafter every 4 weeks with
excellent effect within few days on skin, general condition
and thrive.
Conclusion
To the best of our knowledge we report the first detailed
description of an infant with heterozygous S113L IL36Ra
mutation along with heterozygous Q705K NLRP3 muta-
tion, phenotypically expressed as DITRA with severe gen-
eralized pustular psoriasis. Reduction of the IL36Ra
function will lead to excessive activity of cytokines belong-
ing to the IL-1 family, furthermore the gain-of-function
mutation in NLRP3 will lead to excessive IL-1b and IL-18
production. Collectively, it makes it conceivable that anti-
IL-1 treatment would exert an effect on the disease.
Accordingly anakinra has previously been reported with a
successful result for the treatment of DITRA (1). Also in
our patient anakinra showed a marked effect on general
condition, reduced the eruptions of pustular lesions, but
the erythrodermal changes were preserved and therefore
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only a partial response of the skin lesions could be regis-
tered. However, we demonstrate in this infantile DITRA
patient that TNF-alpha inhibition with infliximab dramati-
cally improved the dermal changes and could normalize
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